The arrival of the drug in the country is sparking significant interest within the healthcare community. This novel dual medication – targeting both GLP-1 and GIP targets – shows a remarkably significant option for https://bookmarkshut.com/story23694645/australia-s-retatrutide-australia-the-new-approach-for-weight-management